Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of patient-reported health-related global and functional quality of life scores from the randomized phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC).

The new analysis of data from LUNAR utilized The European Organization for Research and Treatment of Cancer Quality of Life questionnaire-C30. Analysis showed no statistically significant difference between patients who received TTFields therapy together with standard systemic therapies and patients who received standard systemic therapies alone in median time to deterioration for global health status (4.4 vs 4.0 months, P=0.91) and for all five functional scales: physical functioning (3.2 vs 4.2 months, P=0.58), role functioning (3.0 vs 2.8 months, P=0.59), emotional functioning (6.6 vs 5.7 months, P=0.96), cognitive functioning (3.7 vs 4.4 months, P=0.23), and social functioning (4.0 vs 3.9 months, P=0.66).

Highlights of Novocure’s presentations at the ESMO Congress 2023 also include global post-marketing surveillance data from patients with high-grade gliomas, confirming the well-tolerated safety profile of TTFields therapy in a subgroup of patients ages 70 and older in the real-world setting, which is consistent with data from Novocure’s EF-14 clinical trial. Another highlight is survey data from patients with glioblastoma (GBM) using TTFields therapy in the United States and DACH region (Germany, Austria and Switzerland), which showed that most patients were very satisfied or satisfied with TTFields therapy. Most said they would recommend TTFields therapy to a friend or acquaintance with GBM.

Novocure will also host an industry-sponsored symposium, titled The Evolving Role of TTFields Therapy in Solid Tumors, in Oviedo Auditorium, Hall 7, on Oct. 23 at 1 p.m. CEST.

“We are encouraged by new data supporting the use of TTFields therapy in the management of metastatic NSCLC and further validating the favorable safety and patient satisfaction profiles of TTFields therapy in patients with aggressive central nervous system tumors,” said Pritesh Shah, Novocure’s Chief Growth Officer. “We look forward to sharing these insights with, and continuing to learn from, leading medical oncologists in Europe and worldwide.”

Novocure’s full list of presentations at the ESMO Congress 2023 includes:

  • Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022. Presenter: Wenyin Shi. 12 p.m. CEST on Sunday, Oct. 22.
  • Tumor Treating Fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users. Presenter: Eleni Batzianouli. 12 p.m. CEST on Sunday, Oct. 22.
  • Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study. Presenter: Joachim Aerts. 12 p.m. CEST on Monday, Oct. 23.
  • Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): a systematic literature review (SLR). Presenter: Nikhila Indukuri. 12 p.m. CEST on Saturday, Oct. 21.

Source link :

Newsletter Updates

Enter your email address below and subscribe to our newsletter